Certolizumab pegol Completed Phase 2 Trials for Crohn's Disease (CD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01190410Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
NCT00291668Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
NCT00329420Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)
NCT00329550Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease